Our Vision

Our vision is to grow Consort Medical into the leading customer-centric CDMO that delivers exceptional value to the supply chain from early stage drug and device development to full commercialisation.

Our Strategy

Optimising drug and device services in a single group will streamline and accelerate the route of drugs to market and reduce the cost and complexity of drug/device development for the Group’s pharmaceutical partners. We believe that such an offering is highly differentiated from Consort Medical’s current competitors.

Our Strategy for Sustainable Growth

The Group defines its Strategy for Sustainable Growth in four key elements:

  1. Sustained Organic Revenue Growth

    • Leveraging the Group’s core strengths to win new business from existing and new customers;
    • Broadening and integrating the Group’s services offering to capture business in adjacent markets and territories; and
    • Expanding offering capturing more of the value chain
  2. Operating Leverage

    • Margin expansion from volume growth and ongoing cost efficiency at both Aesica and Bespak
  3. Innovation

    • Drive innovation to develop new device and formulation technologies
  4. Enhancement

    • Selective acquisition of, and investments in, adjacent/complementary technologies/markets